In patients with recurrent breast cancer (BC)
or metastatic breast cancer (mBC)

THERE’S

POWER

IN KNOWING NOW

**Testing for germline BRCA (gBRCA) mutations at workup is recommended by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer in all patients with recurrent BC or mBC — to help identify potential treatment options and inform treatment planning.**¹

NCCN Guidelines®

Learn how gBRCA testing is recommended in all patients with recurrent BC or mBC¹

Variety of patient types

See how gBRCA mutations may be present in different types of patients whom you might not expect²

Help patients move forward with testing

Connect your patients with educational resources and genetic counseling

BC=breast cancer; gBRCA=germline breast cancer susceptibility gene; mBC=metastatic breast cancer; NCCN=National Comprehensive Cancer Network.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer. V.4.2022. June 21, 2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed June 29, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Quek RGW, Mardekian J. Clinical outcomes, treatment patterns, and health resource utilization among metastatic breast cancer patients with germline BRCA1/2 mutation: a real-world retrospective study. Adv Ther. 2019;36(3):708-720.